Inicio4DX • ASX
add
4DMedical Ltd
Cierre anterior
0,56 $
Intervalo diario
0,59 $ - 0,63 $
Intervalo anual
0,41 $ - 0,83 $
Cap. bursátil
250,69 M AUD
Volumen medio
904,84 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
ASX
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(AUD) | jun 2024info | Cambio interanual |
---|---|---|
Ingresos | 1,48 M | 1.172,70 % |
Gastos operativos | 12,56 M | 11,42 % |
Ingresos netos | -10,19 M | -33,78 % |
Margen de beneficio neto | -687,84 | 89,49 % |
Beneficios por acción | — | — |
EBITDA | -11,09 M | -5,51 % |
Tipo impositivo efectivo | -0,01 % | — |
Balance general
Activos totales
Responsabilidades totales
(AUD) | jun 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 30,61 M | -56,01 % |
Activos totales | 120,02 M | 29,16 % |
Responsabilidades totales | 49,09 M | 128,71 % |
Patrimonio total | 70,93 M | — |
Acciones en circulación | 410,53 M | — |
Precio-valor contable | 3,32 | — |
Rentabilidad económica | -23,28 % | — |
Retorno sobre capital | -36,73 % | — |
Flujo de caja
Variación neta del flujo de caja
(AUD) | jun 2024info | Cambio interanual |
---|---|---|
Ingresos netos | -10,19 M | -33,78 % |
Efectivo de operaciones | -8,06 M | 8,54 % |
Efectivo de inversión | -339,48 mil | -21,29 % |
Efectivo de financiación | -233,98 mil | -101,11 % |
Variación neta del flujo de caja | -8,64 M | -172,48 % |
Flujo de caja libre | -5,43 M | 13,25 % |
Información sobre la empresa
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Director ejecutivo
Fundación
2013
Sitio web
Empleados
145